Clinical laboratory-based assay methodologies may underestimate and increase variability of vancomycin protein binding in hospitalized patients

Pharmacotherapy

Volumn 34, Issue 2, 2014, Pages 203-209

  Crandon, Jared L ^a   MacVane, Shawn H ^a   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

Author keywords

FPIA; HPLC; Intensive care unit; Protein binding; Vancomycin

Indexed keywords

VANCOMYCIN; ANTIINFECTIVE AGENT; PROTEIN BINDING;

ADULT; ARTICLE; CLINICAL LABORATORY; CLINICAL PRACTICE; COHORT ANALYSIS; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG PROTEIN BINDING; DRUG SCREENING; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOSPITAL PATIENT; HUMAN; INFECTION; INTENSIVE CARE UNIT; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; PREDICTOR VARIABLE; PROSPECTIVE STUDY; TERTIARY HEALTH CARE; ULTRACENTRIFUGATION; AGED; HOSPITALIZATION; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROCEDURES; STATISTICAL MODEL;

ADULT; AGED; ANTI-BACTERIAL AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COHORT STUDIES; DRUG MONITORING; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; HOSPITALIZATION; HUMANS; INTENSIVE CARE UNITS; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; PROTEIN BINDING; VANCOMYCIN;

EID: 84898028872     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/phar.1323     Document Type: Article

References (23)

1. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin- resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2009;3:e18-55.
2. Rybak MJ, Lomaestro BM, Rotschafer JC, et al. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis 2009;3: 325-7.
3. Moise PA, Forrest A, Bhavnani SM, Birmingham MC, Schentag JJ. Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus. Am J Health Syst Pharm 2000;57(Suppl 2):S4-9.
4. Bailey EM, Rybak MJ, Kaatz GW. Comparative effect of protein binding on the killing activities of teicoplanin and vancomycin. Antimicrob Agents Chemother 1991;6: 1089-92.
5. Drusano GL. Antimicrobial pharmacodynamics: critical interactions of "bug and drug." Nat Rev Microbiol 2004;4: 289-300.
6. Merrikin DJ, Briant J, Rolinson GN. Effect of protein binding on antibiotic activity in vivo. J Antimicrob Chemother 1983;3: 233-8.
7. Nicolau DP, Mattoes HM, Banevicius M, Xuan D, Nightingale CH. Pharmacodynamics of a novel des-F(6)-quinolone, BMS- 284756, against Streptococcus pneumoniae in the thigh infection model. Antimicrob Agents Chemother 2003;5: 1630-5.
8. Vesga O, Agudelo M, Salazar BE, Rodriguez CA, Zuluaga AF. Generic vancomycin products fail in vivo despite being pharmaceutical equivalents of the innovator. Antimicrob Agents Chemother 2010;8: 3271-9.
9. Ackerman BH, Taylor EH, Olsen KM, Abdel-Malak W, Pappas AA. Vancomycin serum protein binding determination by ultrafiltration. Drug Intell Clin Pharm 1988;4: 300-3.
10. Albrecht LM, Rybak MJ, Warbasse LH, Edwards DJ. Vancomycin protein binding in patients with infections caused by Staphylococcus aureus. DICP 1991;7-8: 713-5.
11. Berthoin K, Ampe E, Tulkens PM, Carryn S. Correlation between free and total vancomycin serum concentrations in patients treated for gram-positive infections. Int J Antimicrob Agents 2009;6: 555-60.
12. Chen Y, Norris RL, Schneider JJ, Ravenscroft PJ. The influence of vancomycin concentration and the pH of plasma on vancomycin protein binding. J Pharmacol Toxicol Methods 1992;1: 57-60.
13. Dykhuizen RS, Harvey G, Stephenson N, Nathwani D, Gould IM. Protein binding and serum bactericidal activities of vancomycin and teicoplanin. Antimicrob Agents Chemother 1995;8: 1842-7.
14. Li L, Miles MV, Lakkis H, Zaritsky AL. Vancomycin-binding characteristics in patients with serious infections. Pharmacotherapy 1996;6: 1024-9.
15. Butterfield JM, Patel N, Pai MP, Rosano TG, Drusano GL, Lodise TP. Refining vancomycin protein binding estimates: identification of clinical factors that influence protein binding. Antimicrob Agents Chemother 2011;9: 4277-82.
16. Thom KA, Shardell MD, Osih RB, et al. Controlling for severity of illness in outcome studies involving infectious diseases: impact of measurement at different time points. Infect Control Hosp Epidemiol 2008;11: 1048-53.
17. Hagihara M, Sutherland C, Nicolau DP. Development of HPLC methods for the determination of vancomycin in human plasma, mouse serum and bronchoalveolar lavage fluid. J Chromatogr Sci 2013;51: 201-7.
18. Farin D, Piva GA, Gozlan I, Kitzes-Cohen R. A modified HPLC method for the determination of vancomycin in plasma and tissues and comparison to FPIA (TDX). J Pharm Biomed Anal 1998;3: 367-72.
19. Najjar TA, al-Dhuwailie AA, Tekle A. Comparison of highperformance liquid chromatography with fluorescence polarization immunoassay for the analysis of vancomycin in patients with chronic renal failure. J Chromatogr B Biomed Appl 1995;2: 295-9.
20. Nicholson JP, Wolmarans MR, Park GR. The role of albumin in critical illness. Br J Anaesth 2000;4: 599-610.
21. Zokufa HZ, Solem LD, Rodvold KA, Crossley KB, Fischer JH, Rotschafer JC. The influence of serum albumin and alpha 1-acid glycoprotein on vancomycin protein binding in patients with burn injuries. J Burn Care Rehabil 1989;5: 425-8.
22. Cantu TG, Dick JD, Elliott DE, Humphrey RL, Kornhauser DM. Protein binding of vancomycin in a patient with immunoglobulin A myeloma. Antimicrob Agents Chemother 1990;7: 1459-61.
23. Sun H, Maderazo EG, Krusell AR. Serum protein-binding characteristics of vancomycin. Antimicrob Agents Chemother 1993;5: 1132-6.